Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $64000.0.

  • NewAmsterdam Pharma's Depreciation & Amortization (CF) rose 12857.14% to $64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $212000.0, marking a year-over-year increase of 18266.67%. This contributed to the annual value of $113000.0 for FY2024, which is 13061.22% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Depreciation & Amortization (CF) is $64000.0, which was up 12857.14% from $45000.0 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Depreciation & Amortization (CF) registered a high of $64000.0 during Q3 2025, and its lowest value of $9000.0 during Q1 2023.
  • Its 3-year average for Depreciation & Amortization (CF) is $31000.0, with a median of $23500.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in NewAmsterdam Pharma's Depreciation & Amortization (CF) was 29230.77% (2024), while the steepest drop was 6666.67% (2024).
  • Over the past 3 years, NewAmsterdam Pharma's Depreciation & Amortization (CF) (Quarter) stood at $13000.0 in 2023, then skyrocketed by 292.31% to $51000.0 in 2024, then rose by 25.49% to $64000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $64000.0 in Q3 2025, compared to $45000.0 in Q2 2025 and $52000.0 in Q1 2025.